Fig. 7: TAK-243 suppresses tumor growth in vivo and increases the survival of animals bearing intracranial GSC2-derived tumors. | Cell Death & Disease

Fig. 7: TAK-243 suppresses tumor growth in vivo and increases the survival of animals bearing intracranial GSC2-derived tumors.

From: RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death

Fig. 7

a Representative tumors isolated from the control and TAK-243-treated groups of subcutaneous tumor model. b The mean tumor volumes were assessed at the indicated number of days after tumor implantation. c Tumors isolated from control and TAK-243-treated groups were weighted. The tumor weight was analyzed statistically. d Mice bearing GSC2-derived xenograft tumor were treated with TAK-243 (10 or 20 mg/kg) or vehicle control by intraperitoneally injection twice a week for 4 weeks. Representative images of H&E staining of whole-brain sections from the control group and TAK-243 treatment group. e Kaplan−Meier survival curves of mice implanted with GSC2 cells (n = 10). The survival time of tumor-bearing mice was counted. f Representative IHC staining images of polyubiquitin (polyUb), GRP78, and Ki67 expression in GSC2-derived xenograft tumor of control and TAK-243 treatment groups, scale bar: 50 μm. All the data are expressed as means ± SD. **P < 0.01, ***P < 0.001.

Back to article page